中晚期肝内胆管细胞癌介入治疗的临床疗效分析

目的 评价中晚期肝内胆管细胞癌(ICC)介入治疗效果及分析影响疗效的因素.方法 回顾性分析2007年9月至2014年12月经病理诊断为肝内胆管细胞癌77例患者的临床资料.其中,51例行介入治疗,包括TACE及TACE联合射频消融(RFA)或125I粒子植入术(归为介入组),26例行全身静脉化疗(化疗组).统计分析ICC介入治疗患者的总生存期、肿瘤客观反应率及影响介入疗效的相关因素,同时观察介入治疗后的不良反应和并发症.结果 介入组6、12和18个月生存率分别为70.6％、50.5％和35.4％,中位生存期为12.1个月(95％CI 8.43～15.77);肿瘤客观缓解率及疾病控制率分别为29.4％、70.6％.化疗组6、12和18个月年生存率分别为46.2％、7.7％和0,中位生存期为5.5个月(95％CI 3.38～7.61).单因素分析显示介入治疗组患者中位生存期显著高于化疗组(P＜0.05).对影响介入组患者预后多因素分析显示,血清CA125水平、TNM分期及是否有外科根治术史是影响这类患者预后的独立因素.介入治疗的不良反应主要为骨髓抑制、栓塞后综合征及肝功能损害,均为Ⅰ、Ⅱ级.未出现与介入治疗相关的严重并发症.结论 中晚期ICC行介入治疗是安全可行的,可以控制病情进展及延长患者生存期.     

动脉化疗栓塞辅助手术切除对肝癌患者长期生存的研究

目的 评价动脉化疗栓塞(transarterial chemoembolization,TACE)对可切除肝癌患者生存期的影响.方法 回顾性分析386例因肝癌行部分肝切除术患者的临床资料.全部病例经术后病理证实.根据是否辅以TACE治疗分为TACE组(230例)和非TACE组(156例).TACE组再根据手术与TACE的先后关系分3个亚组:仅术前行TACE者71例为术前TACE组,仅术后行TACE者86例为术后TACE组,术前术后均行TACE者73例为联合TACE组.为比较TACE对肿瘤坏死的影响,术前未行TACE者242例归为A组(非TACE组+术后TACE组),术前行TACE者144例归为B组(术前TACE组+联合TACE组).应用寿命表计算累积生存率,以Kaplan-Meier生存曲线进行生存分析.采用X2检验比较A、B两组肿瘤的坏死率.结果 B组(18/144)较A组(0/242)有较高的肿瘤完全坏死率(P＜0.01).肿瘤完全坏死患者的累积生存率优于不完全坏死者(P＜0.01).患者1、3、5、10年累积生存率:联合TACE组分别为90.4%(66/73)、72.9%(42/73)、51.9%(22/73)和25.4%(2/73),术前TACE组分别为74.0%(50/71)、46.2%(28/71)、27.3%(5/71)和0(0/71),术后TACE组分别为88.0%(73/86)、59.6%(39/86)、36.7%(11/86)和0(0/86),非TACE组分别为75.8%(110/156)、63.4%(48/156)、31.0%(13/156)和23.9%(10/156).联合TACE组疗效最好,优于非TACE组及单纯术前TACE组和术后TACE组(P值均＜0.05).术前或术后TACE组累积生存率与非TACE组比较差异无统计学意义(P值均＞0.05).结论 术前联合术后TACE辅助手术部分肝切除可提高肝癌患者的累积生存率,仅单一术前或术后TACE对患者的远期生存无显著影响.     

影响胰腺癌疗效的多因素分析

目的探讨影响胰腺癌疗效的因素。方法120例胰腺癌进行统计学分析,应用COX比例风险模型对可能影响胰腺癌疗效的指标进行多因素分析,并用Kaplan-Meier法计算生存率。结果肿瘤分期和KPS评分是影响胰腺癌预后的独立因素。结论肿瘤分期和KPS评分是影响胰腺癌治疗后生存期的相关因素。     

原发性肝癌的复合性栓塞治疗

目的：通过对原发性肝癌（PHC）三种介入治疗方法的疗效比较，评估其应用价值。材料和方法：根据不同的治疗方法，分为3组。A组：30例，为单纯动脉内抗癌药灌注（TAI）；B组：15例，为单纯用碘化油动脉栓塞（TA）；C组：45例，碘化油与抗癌药再加明胶海绵复合性动脉栓塞（TACE）。对三组的肿瘤直径缩小率、甲胎蛋白的变化、累计生存率及生存期进行观察对比。结果：TACE组甲胎蛋白降至正常者高于TAI或TAE组（p＜0．01）。TACE组肿瘤缩小率高于TAI或TAE组（p＜0．01）。TACE组累计生存率显著高于TAI或TAE组（p＜0．01）。TACE组平均生存期也高于TAI或TAE组（p＜0．05）。结论：含抗癌药碘油加明胶海绵复合性栓塞治疗原发性肝癌是目前一种比较好的方法。     

微波消融联合TACE治疗原发性肝癌的临床研究

目的 探讨经肝动脉化疗栓塞术(TACE)联合经皮微波凝固治疗(PMCT)对原发性肝癌的治疗效果.方法 将经病理、影像学诊断及AFP值证实的原发性肝癌符合筛选条件的患者共82例,按住院号数的单、双数随机分成2组: 对照组(TACE组)40例,综合治疗组(TACE联合微波消融组)42例,对照组只给予TACE治疗;综合治疗组先行TACE后2～3周再予联合微波消融治疗.结果 TACE组治疗40例患者,1、2、3年生存率分别为70%、54%和20%,中位生存期1.72年;综合治疗组42例患者1、2、3年生存率分别为88%、76%和51%,中位生存期2.1年.综合治疗组的生存率及生存期均显著高于TACE组(P<0.05).结论 肝癌的综合介入治疗可显著提高原发性肝癌的生存率,延长生存期.     

肝动脉化疗栓塞术治疗中晚期肝癌60例效果分析

目的观察经导管肝动脉化疗栓塞术(TACE)治疗中晚期原发性肝癌的疗效。方法采用Seldinger技术,经股动脉穿剌,选择性肝动脉插管灌注化疗联合碘油栓塞(部分病例加用明胶海绵)治疗中晚期原发性肝癌患者中随机选择60例,共行140次介入治疗。结果显效60%(36/60),有效31.7%(19/60),稳定8.7%(5/60),生存率显著提高,12个月以上生存率达63.3%(38/60)。结论TACE治疗中晚期原发性肝癌疗效确切,能够显著延长生存期,提高生存质量。     

高强度聚焦超声与肝动脉化疗栓塞联合治疗原发性肝癌

目的:探讨中晚期肝癌和位于肝门区肝癌先行肝动脉化疗栓塞(TACE)、再行高强度聚焦超声(HIFU) 治疗的意义。方法:对近年符合条件的30例肝癌患者先行TACE,而后进行HIFU治疗。另30例肝癌患者直接 给予TACE治疗。治疗后定期复查甲胎蛋白(AFP),一个月后复查超声或CT、MRI确定肿瘤是否完全坏死,以后 每3个月复查。结果:TACE加HIFU组肿瘤完全坏死率86.6%(26/30),单纯TACE组23.3%(7/30),差异有显 著意义。前组AFP转阴率73.9%(17/23),后组18.6%(5/27);前组6个月无瘤生存率100%(30/30),后组 76.6%(23/30);前组1年生存率为100%,后组1年生存率为73.3%,差异有显著意义。结论:对中晚期肝癌、位于 肝门区肝癌、边界不清的或多个病灶的肝癌先行TACE,再适时给予HIFU,可以扩大肿瘤坏死范围,增加肿瘤完全 坏死率,减少复发,提高生存率。     

经肝动脉化疗栓塞对高危因素肝癌的疗效观察

目的 探讨经肝动脉化疗栓塞(TACE)对高危因素肝癌的治疗效果.方法 回顾性分析2001年1月至2005年12月266例肝癌患者接受536次介入治疗,患有门静脉癌栓或血胆红素升高(＞34 μmoL/L)者为高危组,余患者为低危组.高危组74例(27.8%),低危组192例.高危组采用更加超选择性栓塞、较少的栓塞剂用量和较少的手术次数(为1.4和2.3 P＜0.05),比较两组患者的术后并发症发生率、生存期.结果 全部并发症的发生率为3.5%,两组并发症的发生率差异无统计学意义(分别为2.5和7.6%,P=0.07),高危组1、3年生存率分别为45%和16%,低危组1、3年生存率分别为63%和18%,低危组生存期长于高危组,但两组间差异无统计学意义(P=0.08).结论 高危因素肝癌患者TACE术后并发症发生率未显著增加.采用适当的技术,TACE对高危因素肝癌患者是安全的.     

大肝癌的综合性微创介入治疗研究及预后分析

【摘要】目的：分析经肝动脉灌注化疗栓塞术（TACE）和TACE+射频消融（RFA）两种治疗方案对原发性大肝癌的疗效,并分析大肝癌的预后影响因素,旨在探索出一套规范化的介入治疗模式,提高大肝癌的治疗效果,并为大肝癌的预后评估提供理论依据。方法：回顾性分析50例行TACE及TACE+RFA介入方案治疗的原发性大肝癌患者的病例资料,记录患者的一般资料、治疗情况、肿瘤情况、检查情况等,并观察患者病情的变化情况。对影响肝癌治疗及预后的相关因素行Cox回归分析。结果：TACE+RFA组肿瘤有效缩小率为70%,TACE组肿瘤有效缩小率为33.33%,差异有统计学意义（P＜0.05）。TACE组和TACE+RFA组治疗前后AFP差值差异有统计学意义（Z=-2.020,P＜0.05）。TACE组和TACE+RFA组术后6个月、1年及2年的生存率分别为83.33%、56.67%、30.00%和90.00%、75.00%、55.00%,其中位生存期分别为13个月和17个月,两组生存率差异有统计学意义（χ2=4.059,P＜0.05）。Cox回归多因素分析表明,HbsAg(+)、治疗前主瘤直径、治疗方式及治疗后肿瘤有效缩小率与预后显著相关。结论：TACE+RFA疗效显著优于单纯TACE。HbsAg(+)、治疗前主瘤直径、治疗方式及治疗后肿瘤缩小率是影响大肝癌介入治疗预后的重要因素。     

原发性肝癌双介入治疗疗效的临床研究

目的 评价双介入方法治疗原发性肝癌的临床应用价值.方法 选择2001年3月至2003年2月在我院进行介入治疗的原发性肝癌患者68例,其中,单纯性肝动脉化疗栓塞36例(TACE组),行肝动脉化疗栓塞(TACE)和经皮肝穿注射无水乙醇(PEI)双介入治疗32例(双介入组).全部病例定期做CT复查和AFP测定,观察肿瘤的客观疗效.结果 TACE组肿瘤客观有效率(CR PR)36.1%,AFP下降幅度56.1%,2 a生存率44.4%;双介入组客观有效率65.7%,AFP下降幅度78.6%,2 a生存率62.5%,两组间有显著差异(P＜0.05).结论 双介入方法治疗原发性肝癌疗效肯定,优于单纯应用TACE.     

CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement

Purpose

To assess the time to disease progression (TTP), long-term survival benefit and safety of patients with unresectable hepatocellular carcinoma (HCC) treated with computed tomography (CT)-guided radiofrequency ablation (RFA) with transarterial chemoembolization chemoembolization (TACE).

Methods

This study was approved by the institutional review board. We reviewed the records of patients with intermediate and advanced HCC treated with CT-guided RFA with TACE between January 2000 and December 2009. Median TTP, overall survival (OS) and hepatic function were analyzed with the Kaplan–Meier method and log-rank tests.

Results

One hundred and twenty-two patients (112 men and 10 women, mean age 53 years, range 18–86 years) were included in the study. The median follow-up time was 42 months (range 6–89 months), TTP was 6.8 months, the median OS was 31 months, and the 1-, 3-, and 5-year OS were 88.5%, 41.0%, and 10.7%. The results of the univariate analysis revealed that intrahepatic lesion, AJCC stage, and Child-Pugh stage were predictors of OS (P < 0.01). In the multivariate analysis, the AJCC stage system showed a statistically significant difference for prognosis. Procedure-related death was 0.21% (1/470) within 1 month, and a statistical difference was found between the TACE and RFA of liver decompensation and Child-Pugh stage (P < 0.05).

Conclusions

The survival probabilities of OS increased with CT-guided RFA with TACE, as observed in randomized studies from Europe and Asia. The longest TTP was observed for the intermediate stage HCC. The procedures were well tolerated with acceptable minor and major complications in unresectable HCC patients.     

Current status of transarterial radioembolization

Unresectable primary and secondary liver malignancies present a major problem in the treatment of solid tumors. Transarterial radioembolization (TARE) is an increasingly used technique for treating various types of malignant liver tumors. This approach is appealing, as the mechanism of action is independent from other loco-regional treatments and potentially complementary to systemic therapies. There are two commercially available products in use for TARE: ⁹⁰Y-resin and ⁹⁰Y-glass microspheres. Currently available data indicates TARE so be safe and effective in hepatocellular carcinoma (HCC) and metastatic liver disease. In HCC the results compare well with chemoembolization, while the role of TARE in combination with kinase inhibitors has yet to be established. Current data on TARE in metastatic liver disease is promising, but there is a strong need for prospective randomized trials comparing TARE and modern chemotherapeutic regimen to support the growing role of TARE in metastatic liver disease.     

Preoperative transarterial Embolisation in bone tumors

Bone tumors include a variety of lesions, both primary and metastatic. The treatment modalities for bone tumors vary with the individual lesion, but in general surgical excision is the treatment of choice with other adjunctive therapies. However, surgery for many bone tumors is complex due to several factors including tumor bulk, vascularity, vicinity to vital structures and potentially inaccessible location of the lesion. Transarterial Embolisation (TAE) is one of the important adjuvant treatment modalities and in some cases it may be the primary and curative treatment. Preoperative TAE has proved to be effective in both primary and metastatic bone tumors. It reduces tumor vascularity and intraoperative blood loss, the need for blood transfusion and associated complications, allows better definition of tissue planes at surgery affording more complete excision, and hence reduced recurrence. Preoperative chemoEmbolisation has also been shown to increase the sensitivity of some tumors to subsequent chemotherapy and radiotherapy. There are several techniques and embolic agents available for this purpose, but the ultimate aim is to achieve tumor devascularization. In this review, we discuss the techniques including the choice of embolic agent, application to individual lesions and potential complications.     

乳腺癌DSA造影及术前超选择性动脉化疗栓塞

目的 探索乳腺癌的血供特点及术前超选择性动脉化疗栓塞的临床应用价值.方法 48例经穿刺活检确诊乳腺癌患者,采用术前DSA造影评估乳腺癌供血动脉分布,分别超选择性插管化疗栓塞.结果 48例患者DSA造影共发现74支明确供血动脉.单支供血9例,多支供血39例,主要以胸外侧动脉和(或)胸廓内动脉为主.灌注化疗后手术切除的近期...     

Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma

Purpose The aim of this prospective study was to evaluate the feasibility, safety, and efficacy of sequential transarterial chemoembolization (TACE) for patients with unresectable advanced hepatocellular carcinoma (HCC). Methods Twenty-one consecutive patients with unresectable T3 and T4 HCC were treated by sequential TACE (median time interval between treatments 7 weeks) up to six times with an emulsion of lipiodol, epirubicin, and cisplatin. All TACE procedures were performed as unilobar or whole-liver chemoembolization. Results An average of 3.9 TACE procedures were performed per patient. One primary and two secondary technical failures occurred. No procedural death was observed. After exclusion of the patient with the primary technical failure and 3 patients with extrahepatic disease, the survival rates for the remaining 17 patients at 6, 12, 18, and 24 months were 70.6%, 52.9%, 44.1%, and 33.1%, respectively. Conclusion Sequential TACE is a safe procedure in patients with unresectable advanced HCC and feasible in most cases. It seems to prolong the survival time compared with historical series of untreated patients.     

Acute ischemic cholecystitis after transarterial chemoembolization with drug-eluting beads

Transarterial chemoembolization (TACE) is a widely used treatment choice for hepatocellular cancer. DC Bead microspheres are a new embolic material for TACE that doxorubicin can be loaded to. The tumor response rate of this well-tolerated treatment was changed between 60% and 81.8%. We report a case of ischemic cholecystitis after TACE with drug-eluting beads (DEB) that required cholecystectomy. The possibility of cholecystitis is always remembered during TACE-DEB for tumors in segment IV and/or V. Although selective catheterization is related with a lower risk for ischemic cholecystitis, the anatomic and vascular variability in patients with malignancy may lead to some unexpected conditions.     

肝癌动脉化疗栓塞致截瘫病例分析

目的探讨化疗栓塞术后发生截瘫的病因、临床特点和预防。方法2003年3月-2005年2月共有2758例肝肿瘤患者施行经导管动脉化疗栓塞术(TACE),术后发生截瘫4例。本研究详细回顾手术过程和术后病程。结果4例患者TACE术后4 h内出现截瘫症状,截瘫发生率为0.145%,并在24～48 h症状进行性加重,5～7 d后病情逐渐平稳,2个月后症状明显改善。结论肝肿瘤患者多次栓塞化疗后及远处转移瘤行供血动脉化疗栓塞时需慎重,尽量预防脊髓动脉栓塞。     

Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma

Purpose

To compare short- and long-term clinical outcomes after conventional transarterial chemoembolization and drug-eluting bead (DEB) transarterial chemoembolization in hepatocellular carcinoma (HCC).

Materials and Methods

Patients with unresectable HCC unsuitable for ablative therapies were randomly assigned to undergo conventional or DEB chemoembolization. The primary endpoints of the study were safety, toxicity, and tumor response at 1 month. Secondary endpoints were number of repeated chemoembolization cycles, time to recurrence and local recurrence, time to radiologic progression, and survival.

Results

In total, 67 patients (mean age, 70 y ± 7.7) were evaluated. Mean follow-up was 816 days ± 361. Two periprocedural major complications occurred (2.9%) that were treated by medical therapy without the need for other interventions. A significant increase in alanine aminotransferase levels 24 hours after treatment was reported, which was significantly greater after conventional chemoembolization (n = 34) than after DEB chemoembolization (n = 33; preprocedure, 60 IU ± 44 vs 74 IU ± 62, respectively; at 24 h, 216 IU ± 201 vs 101 IU ± 89, respectively; P = 0.007). No other differences were observed in liver toxicity between groups. At 1 month, complete and partial tumor response rates were 70.6% and 29.4%, respectively, in the conventional chemoembolization group and 51.5% and 48.5%, respectively, in the DEB chemoembolization group. No differences were observed between groups in time to recurrence and local recurrence, radiologic progression, and survival.

Conclusions

Conventional chemoembolization and DEB chemoembolization have a limited impact on liver function on short- and long-term follow-up and are associated with favorable clinical outcomes.